Ajoke Sobanjo-ter Meulen is a globally recognized vaccine and global health expert with deep experience in vaccine development and strategy leadership positions in the pharmaceutical, and biotechnology industry, at the Gates Foundation, and in global health organizations. Most recently Ajoke served as Vice President Medical Affairs & Policy at AstraZeneca, leading Medical Affairs for the first  hMPV/RSV combination vaccine candidate, and supporting the transition following AstraZeneca's acquisition of Icosavax, a Seattle-based biotechnology company. Previously,  Ajoke was a Senior Program Officer with the Gates Foundation, where she led the foundation’s maternal immunization initiative. In her prior role as Cluster Head at Novartis Vaccines, Cambridge, she managed the Phase 2 maternal immunization clinical development program for the Group B streptococcus vaccine. She also served as Associate Director Vaccine Clinical Research at Merck Research Laboratories, leading clinical development activities from discovery through phase 3. Before joining industry, she coordinated the Child Health and Neglected Diseases program at the German bilateral agency (GIZ), as well as a large multi-center trial on HIV drug resistance monitoring and surveillance in Africa and Asia for the Netherlands Aids Foundation. Ajoke completed her residency in pediatric and adolescent medicine at the University of Wuerzburg, Germany, and did her pediatric infectious disease fellowship at Mount Sinai Medical School, New York. She holds a M.D. degree from the University of Berlin, a Dr. med. degree from the Bernhard Nocht Institute of Tropical Medicine Hamburg; and a M.Sc. degree in Epidemiology from the London School of Hygiene and Tropical Medicine.